Allthe synthesized compounds were evaluated over U251 EphA2 overexpressedand U251 wild-type GBM cell lines, where 295 and 296 were found to be the promising compounds in series whichactivity is shown in the figure. This evidence concerns the gene EPHA2 and glioblastoma.